Pharma Distrust: Between Evidence-Based Medicine and Conspiracy TheoriesλPharma Distrust: Between Evidence-Based Medicine and Conspiracy Theories

Trust Statistics: 71 out of 100 and Its Meaning

The American pharmaceutical industry received a trust rating of 71/100 in 2023. This figure conceals a paradox: moderate trust in the system coexists with deep skepticism toward specific medications and recommendations.

Patients demonstrate contradictory attitudes—simultaneously trusting medical organizations while doubting their advice. This discrepancy between general trust and actual behavior creates a phenomenon of "statistical trust" that doesn't translate into decisions about taking medications.

Post-Pandemic Effects: How COVID-19 Changed the Trust Landscape

The COVID-19 pandemic radically transformed attitudes toward the healthcare system and pharmaceuticals. Polarization occurred: simultaneous strengthening of both trust and distrust in medical institutions.

Accelerated vaccine development and emergency drug approvals created grounds for conspiracy theories about pharmaceutical companies "rushing," amplifying existing distrust in clinical trials.

Social perceptions of medical organizations became more polarized, while behavioral patterns often don't align with stated attitudes. Those who formally "trust" the system simultaneously seek information from unofficial sources and verify doctors' prescriptions.

Regional Differences: The Geography of Distrust

Trust levels in the pharmaceutical industry vary across the United States. Differences stem from unequal access to quality medical care, population education levels, and local cultural characteristics in perceiving medicine.

Developed regions (major cities)

Higher trust in evidence-based medicine, better access to information about clinical trials, higher health literacy.

Remote areas

Adherence to traditional practices, skepticism toward "official" pharmaceuticals, limited access to quality medical information.

Intermediate regions

Mixed attitudes: trust in local doctors while simultaneously distrusting federal recommendations and large pharmaceutical companies.

"Evidence-Based Medicine Against Doctors and Patients"

The first two myths claim that EBM is directed against doctors and against patients. The myth about opposing doctors is based on the misconception that standardized protocols undermine clinical experience and professional autonomy.

The myth about opposing patients is built on the belief that unified approaches ignore individual needs and turn treatment into an assembly line. In reality, evidence-based medicine integrates three components: best scientific evidence, clinical expertise, and patient preferences.

1. Scientific evidence — results of clinical trials and systematic reviews
2. Clinical expertise — physician's experience, knowledge of the specific patient's characteristics
3. Patient preferences — their values, fears, life circumstances

"Evidence-Based Medicine Serves Big Pharma"

The third myth — a conspiracy theory about pharmaceutical corporations controlling medical science. According to this narrative, clinical trials are sponsored by drug manufacturers to obtain favorable results, while independent research is suppressed.

The myth is fueled by real cases of conflicts of interest in the pharmaceutical industry, but extrapolates isolated violations to the entire evidence-based medicine system.

The term "pharmaceutical conspiracy theory" describes general patient distrust of the medical community and corporations, creating a barrier to accepting scientifically grounded recommendations.

Distrust of Clinical Trials and "Hidden Drugs"

The fourth and sixth myths concern distrust of clinical trial methodology and belief in the existence of "hidden effective drugs." Patients doubt the reliability of randomized controlled trials, not understanding the rigorous protocols for testing safety and efficacy.

Simultaneously, there exists a belief that doctors intentionally conceal effective treatments — a narrative rooted in the Soviet era with its myths about "secret medicines." The fifth myth about the superiority of "natural" over synthetic complements this picture, creating a preference for unproven traditional remedies over drugs with proven efficacy.

• Randomized controlled trials — the gold standard for testing efficacy, eliminating subjectivity
• Double-blind testing — neither doctor nor patient knows who receives the drug or placebo
• Pre-registration of results — protection against data manipulation
• Publication of negative results — mandatory disclosure of failed trials

Historical Roots: The Myth of Classified Developments

Belief in the existence of "secret Soviet medicines" formed a persistent pattern of distrust toward official medicine that persists in modern Russia.

During the Soviet period, the secrecy of medical developments and limited access to information about pharmaceutical research created fertile ground for mythologizing "special" drugs available only to the elite. This narrative generated unrealistic expectations about pharmaceutical capabilities and the conviction that effective medicines are intentionally hidden from the general public.

Historical attitudes continue to influence modern perceptions of the pharmaceutical industry, creating a preference for "hidden" or "special" treatment methods over standard protocols.

Impact on Modern Attitudes: From USSR to "Big Pharma"

The Soviet legacy has transformed into modern skepticism toward the global pharmaceutical industry, while preserving the basic structure of distrust.

Paradox: a high trust score of 71/100 coexists with widespread distribution of drugs with unproven efficacy. Homeopathic Oscillococcinum is found in 2/3 of Montreal pharmacies, despite the absence of scientific evidence.

The contradiction between formal trust and actual consumption of unproven remedies demonstrates the depth of historically conditioned distrust toward evidence-based medicine.

Oscillococcinum and Other Examples of Mass Delusion

The homeopathic remedy Oscillococcinum is found in two-thirds of Montreal pharmacies, despite a complete absence of scientific evidence for its effectiveness. This phenomenon is not limited to one city or country—unproven medications constitute a significant segment of the pharmaceutical market in many countries, including the United States.

Their presence on pharmacy shelves creates an illusion of medical legitimacy: consumers logically assume that regulators would not allow ineffective products to be sold. The paradox is that the very availability of such medications undermines trust in the pharmaceutical system as a whole.

If pharmacies sell placebos, how can we distinguish them from medications that actually work?

Regulatory Failures and Conflicts of Interest

The problem of regulating unproven medications is rooted in the contradiction between scientific standards and commercial interests. Research on recommendations for cephalgia (headache) revealed substantial discrepancies between rational medical prescriptions and pharmacist advice in drugstores.

1. Self-medication culture: patients rely on pharmacist recommendations, which may be motivated by commercial profit rather than evidence base.
2. Regulatory agencies balance between consumer protection and the economic interests of the pharmaceutical industry.
3. Result: space for medications whose effectiveness is not confirmed by rigorous clinical trials.

Erosion of Trust Through the Presence of Ineffective Products

The presence of unproven medications on the market creates a cascading effect of distrust. When patients discover they have spent money on an ineffective product, their skepticism spreads to the entire pharmaceutical system, including medications that actually work.

This is particularly dangerous in the context of evidence-based medicine: each case of disappointment with an ineffective medication reinforces myths that "clinical trials are unreliable" and "EBM serves the interests of Big Pharma." This vicious cycle makes it difficult to implement scientifically sound approaches to treatment.

Typology of Conspiracy Theories in Pharmaceuticals

Pharmaceutical conspiracy theories form a systematic structure of distrust, encompassing all levels of the medical system. Three key narratives—"EBM against doctors," "EBM against patients," and "EBM serves Big Pharma"—are not isolated but form an interconnected belief system where each element reinforces the others.

The myth of hidden effective treatments is historically rooted in narratives about "secret medicines," creating unrealistic expectations and distrust of official medicine. Modern conspiracy theories expand the spectrum: manipulation of laboratory test results, concealment of data by pharmaceutical companies, global control schemes.

Conspiracy narratives offer simple explanations for complex phenomena—this is their main psychological strength and their main danger.

Psychological Mechanisms of Conspiratorial Thinking

The appeal of pharmaceutical conspiracy theories is rooted in cognitive mechanisms that simplify reality. The post-pandemic period revealed a paradox: simultaneous trust and distrust in medical organizations, a disconnect between social perceptions and actual behavior when seeking help.

This cognitive dissonance is resolved through conspiracy narratives. Regional differences in levels of trust in healthcare show that conspiratorial thinking is not universal but depends on local context and historical experience.

1. Simplification of complexity through a single enemy (Big Pharma, government, elites)
2. Reinterpretation of random coincidences as patterns
3. Rejection of scientific rationality in favor of intuitive judgments ("natural is always better")
4. Distrust of clinical trials as instruments of control

Social Consequences and Healthcare Barriers

The spread of conspiracy theories creates measurable barriers to effective healthcare. Patients refuse evidence-based treatments in favor of unproven alternatives—particularly dangerous with serious diseases where delay can be fatal.

Distrust of laboratory tests leads to ignoring important diagnostic data. Economic losses: patients spend money on ineffective drugs, the healthcare system bears costs from complications that could have been avoided with timely treatment.

Clinical Trial Phases and International Protocols

Clinical trials follow a four-phase system developed by the international scientific community. Each phase addresses a specific objective: the first tests safety on healthy volunteers, the second examines efficacy and dosage on patients with the target condition, the third compares the drug with existing treatments on a large sample, and the fourth monitors side effects after approval.

These protocols are regularly updated based on accumulated experience. Standards include requirements for sample size, observation duration, patient inclusion/exclusion criteria, and statistical analysis methods.

International Guidelines and Standards Harmonization

The FDA (USA), EMA (Europe), and national regulators have developed unified requirements for clinical research. Harmonization ensures mutual recognition of results and accelerates patient access to innovative drugs.

However, the stringency of these standards means lengthy timelines and high development costs. This paradox fuels conspiracy theories about pharmaceutical companies hiding data: people see only delays and prices, but not the system of checks that ensures them.

The Gap Between Scientific Standards and Public Understanding

The public is unaware of the multi-layered verification system that every drug undergoes. Scientific communication uses specialized language, while media simplify or sensationalize information about clinical research.

A trust rating of 71/100 for American pharmaceuticals alongside widespread myths about evidence-based medicine demonstrates that formal trust does not correlate with understanding of scientific processes.

This gap is a key factor in distrust. People don't distinguish between the rigor of standards and their transparency to the public. The result: a drug has passed all checks, but a person remains uncertain because they don't understand what exactly was tested and why it matters.

1. Scientific standards exist and are regularly updated
2. Information about them is inaccessible to the general audience
3. Media and conspiracy theories fill the information vacuum
4. Distrust grows not from lack of checks, but from their invisibility